This study is about testing a drug called Talazoparib for treating a type of breast cancer that has spread to other parts of the body. This cancer must have a change (mutation) in either the BRCA1 or BRCA2 genes. The study is a Phase II trial, which means that it checks if the drug is safe and works well. The drug stops proteins known as PARPs that usually help fix broken DNA. If these proteins are stopped, it can help kill cancer cells.

For a person to join, their cancer must have a certain kind of BRCA mutation. The cancer can be either triple-negative (lacking three common markers) or hormone receptor positive (responds to hormones) but must have spread and not responded to other treatments.

• The trial lasts several weeks and involves taking the study drug.
• Participants will need regular check-ups and blood tests.
• There might be side effects as the drug is investigational.

Participants must be over 18, have specific health criteria, and cannot be pregnant. If interested, talking to a doctor to understand the trial details is important.